Section VI:Probiotics,Prebiotics and Postbiotics——Probiotics Session 3:Synthetic Biology and Next-Generation Probiotic Development |
2026-03-13 09:00-12:00 BFA,Main Hall1/2-A,Level 2 |
| |
| 2026-03-13 09:00-09:05 |
| 2026-03-13 09:05-09:25 Clinical Evidence:New Strategies to Drive Probiotic Viability and Efficacy Research |
| 2026-03-13 09:25-09:45 Construction of an Ultrahigh-Throughput Microbial Screening Platform Based on Automation and Multidimensional Phenotyping:Industrial Application |
| 2026-03-13 09:45-10:00 The patented strain CCFM8631 empowers body management,from metabolic regulation mechanisms to clinical evidence |
| 2026-03-13 10:00-10:15 From Concept to Gold Standard:Clinical Validation Reshaping the Core Competitiveness of Probiotic Products |
| 2026-03-13 10:15-10:35 From Mechanistic Exploration to Population Validation:Evidence-Based Medical Research on Seven-Strain Compound Probiotics and Their Functional Yogurt |
| 2026-03-13 10:35-10:55 Health Benefits of Probiotic Supplementation in Early Life:A Population-Based Real-World Study of 10,000 Subjects |
| 2026-03-13 10:55-11:10 From Research to Commerce:Health Solutions Targeting Gut Microbiota |
| 2026-03-13 11:10-11:30 Clinical Evidence-Based Research Progress of Highly Active Spore Probiotic BC99 |
| 2026-03-13 11:30-11:55 Launch of Highly Active Spore Probiotic BC99 |
| 2026-03-13 11:55-12:00 Application Launch of Highly Active Probiotic Products |
